Gilead Sciences | GILD - 流動負債





流動負債 変化する 日付
AbbVie USD 41.64B 458M 2026-06
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Alnylam Pharmaceuticals USD 2.06B 550.49M 2026-09
Amgen USD 25.5B 547M 2026-06
Biogen USD 3.9B 18.7M 2026-09
BioMarin Pharmaceutical USD 1.6B 59.17M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Coherus Biosciences USD 75.51M 56.82M 2026-06
Eli Lilly USD 47B 745M 2026-09
Gilead Sciences USD 12B 982M 2026-09
GlaxoSmithKline GBP 20.72B 814M 2026-09
Glaxosmithkline GBP 20.72B 1.71B 2026-09
Incyte USD 1.44B 125.72M 2026-09
J&J USD 55.46B 562M 2026-09
Merck USD 27.73B 786M 2026-06
Moderna USD 2.53B 139M 2026-06
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Novartis USD 32.52B 777M 2026-09
Pfizer USD 32.65B 1.7B 2026-06
PTC Therapeutics USD 776.08M 5.01M 2026-09
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 29.77B 2.16B 2026-09
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
United Therapeutics USD 607.8M 8.7M 2026-06
Vertex Pharmaceuticals USD 5B 1.06B 2026-09